Loading...

Enanta Pharmaceuticals, Inc.

ENTA•NASDAQ
HealthcareBiotechnology
$5.96
$0.21(3.65%)

Enanta Pharmaceuticals, Inc. (ENTA) Stock Overview

Explore Enanta Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth
-14.61%
↓ 14.61%
Profit Growth
$-4.53
↑ 13.28%
EPS Growth
$-4.53
↑ 14.11%
Operating Margin
-158.40%
↑ 11.31%
ROE
-69.41%
↑ 13.28%
Dividend Yield
0.00%

Analyst Recommendations

Strong Buy
0
Buy
2
Hold
0
Sell
0
Strong Sell
0

Price Targets

Low$0.00
Average$0.00
High$0.00

Company Profile

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

CEO

Dr. Jay R. Luly Ph.D.

Employees

131

Headquarters

500 Arsenal Street, Watertown, MA

Founded

2013

Frequently Asked Questions

Meyka LogoMeyka

Meyka is the best Alternative Data platform powered by AI providing research insights for investors

Connect With Us

Legal

Resources

Market

Legal Disclaimer

The information provided by Meyka AI PTY LTD is for informational and research purposes only and does not constitute financial, investment, or trading advice. Meyka is a research platform, not a financial advisory service. Investing in financial markets involves risks, and past performance does not guarantee future results. Users should conduct their own due diligence, consult with professional financial advisors, and assess their risk tolerance before making investment decisions. Meyka and its operators are not liable for any financial losses incurred from the use of information on this platform. The data provided is derived from publicly available sources and is believed to be reliable but may not always be accurate or up to date. Users should independently verify information and not rely solely on Meyka for financial decisions. By using Meyka, you acknowledge that it does not provide financial advice or recommendations and agree to seek guidance from a qualified financial professional before making any investment decisions.

© 2025 Meyka AI PTY LTD. All rights reserved.